Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States
Mark W. Tenforde, Manish M. Patel, Adit A. Ginde, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
Mark W. Tenforde, Wesley H. Self, Katherine Adams, et al.
JAMA (2021) Vol. 326, Iss. 20, pp. 2043-2043
Open Access | Times Cited: 586
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
Hana M. El Sahly, Lindsey R. Baden, Brandon Essink, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 19, pp. 1774-1785
Open Access | Times Cited: 571
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
Wesley H. Self, Mark W. Tenforde, Jillian P. Rhoads, et al.
MMWR Morbidity and Mortality Weekly Report (2021) Vol. 70, Iss. 38, pp. 1337-1343
Open Access | Times Cited: 421
Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US
Jing Sun, Qulu Zheng, Vithal Madhira, et al.
JAMA Internal Medicine (2021) Vol. 182, Iss. 2, pp. 153-153
Open Access | Times Cited: 238
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
Karin Bok, Sandra Sitar, Barney S. Graham, et al.
Immunity (2021) Vol. 54, Iss. 8, pp. 1636-1651
Open Access | Times Cited: 230
BNT162b2 Protection against the Omicron Variant in Children and Adolescents
Ashley M. Price, Samantha M. Olson, Margaret M. Newhams, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 20, pp. 1899-1909
Open Access | Times Cited: 221
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche, Liêm Binh Luong Nguyen, Éric Tartour, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 163-177
Open Access | Times Cited: 175
COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022
Fiona P. Havers, Huong Pham, Christopher A. Taylor, et al.
JAMA Internal Medicine (2022) Vol. 182, Iss. 10, pp. 1071-1071
Open Access | Times Cited: 150
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
Monika Kumari, Ruei‐Min Lu, Mu‐Chun Li, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 111
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021
Kristina L. Bajema, Rebecca M. Dahl, Mila M. Prill, et al.
MMWR Morbidity and Mortality Weekly Report (2021) Vol. 70, Iss. 37, pp. 1294-1299
Open Access | Times Cited: 109
Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas
Paul A. Christensen, Randall J. Olsen, Sheng Long, et al.
American Journal Of Pathology (2021) Vol. 192, Iss. 2, pp. 320-331
Open Access | Times Cited: 109
Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
Samantha M. Olson, Margaret M. Newhams, Natasha Halasa, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 8, pp. 713-723
Open Access | Times Cited: 104
Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant
Kasama Manothummetha, Nipat Chuleerarux, Anawin Sanguankeo, et al.
JAMA Network Open (2022) Vol. 5, Iss. 4, pp. e226822-e226822
Open Access | Times Cited: 87
Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review
Edward P K Parker, Shalini Desai, Melanie Marti, et al.
The Lancet Global Health (2022) Vol. 10, Iss. 3, pp. e326-e328
Open Access | Times Cited: 81
Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant
Ai‐ris Y. Collier, Catherine Brown, Katherine McMahan, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 641
Open Access | Times Cited: 75
An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam
Nguyen Van Vinh Chau, Nghiêm My Ngoc, Lam Anh Nguyet, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101143-101143
Open Access | Times Cited: 97
COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
Piotr Rzymski, Carlos A. Camargo, Andrzej Fal, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1299-1299
Open Access | Times Cited: 76
Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review
Kadhim Hayawi, Sakib Shahriar, Mohamed Adel Serhani, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1305-1305
Open Access | Times Cited: 58
Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis
Alexandre R. Marra, Takaaki Kobayashi, Hiroyuki Suzuki, et al.
Journal of Infection (2022) Vol. 84, Iss. 3, pp. 297-310
Open Access | Times Cited: 56
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months
Caroline M. Hsu, Daniel E. Weiner, Harold J. Manley, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 3, pp. 403-413
Open Access | Times Cited: 53
Associations between persistent symptoms after mild COVID‐19 and long‐term health status, quality of life, and psychological distress
Jin H. Han, Kelsey N. Womack, Mark W. Tenforde, et al.
Influenza and Other Respiratory Viruses (2022) Vol. 16, Iss. 4, pp. 680-689
Open Access | Times Cited: 50
Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients
Robert Whittaker, Anja Bråthen Kristofferson, Beatriz Valcárcel Salamanca, et al.
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 6, pp. 871-878
Open Access | Times Cited: 47
Nanomaterials for mRNA‐based therapeutics: Challenges and opportunities
Defeng Li, Qisong Liu, Meifeng Yang, et al.
Bioengineering & Translational Medicine (2023) Vol. 8, Iss. 3
Open Access | Times Cited: 36
Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years in the United States
Brenna Kirk, Christopher Bush, Astra Toyip, et al.
Vaccine (2024) Vol. 42, Iss. 25, pp. 126113-126113
Open Access | Times Cited: 7
Current view on novel vaccine technologies to combat human infectious diseases
Zrinka Matić, Maja Šantak
Applied Microbiology and Biotechnology (2021) Vol. 106, Iss. 1, pp. 25-56
Open Access | Times Cited: 53
Page 1 - Next Page

Scroll to top